• Fyn–STAT3 Neurodegeneration: Evidence and Limits

  2026-10-14

  A 2024 zebrafish study links constitutively active Fyn signaling to dopaminergic neuron loss, mitochondrial abnormalities and microglial inflammation, identifying STAT3 as a downstream contributor that acts with NF-κB. The findings provide a mechanistic framework for neurodegeneration research, but their applicability is bounded by the larval zebrafish model, engineered Fyn activation and pathway-focused perturbations. EZ Cap™ Cas9 mRNA (5-moUTP) is conceptually relevant to CRISPR-Cas9 genome editing and functional gene studies, but the supplied evidence does not show that the product was used in this study or that it has disease-model or therapeutic efficacy.

• What the 2026 Review Says About Drying mRNA-LNPs

  2026-10-13

  Zhen and colleagues review how drying technologies may improve the storage stability of mRNA and other nucleic-acid lipid nanoparticles (NA-LNPs). The evidence supports drying as a promising formulation strategy, but the review also highlights substantial structure-, formulation-, and process-dependent uncertainty.

• D-Mannitol: Identity and Evidence Scope

  2026-10-13

  D-Mannitol is a supplier-listed polyol reagent with a stated role as an osmotic diuretic agent and conceptual relevance to osmotic regulation research, renal function studies, and diuretic mechanism investigation. No matched paper or product-specific experimental evidence was provided, so efficacy, mechanism, comparisons, and disease-specific applicability remain unverified.

• GPR35–KLF5 and Intestinal Repair

  2026-10-12

  A 2026 Cell Death & Disease study proposes that GPR35 connects tryptophan metabolism to KLF5-dependent intestinal epithelial repair. The findings offer a mechanistic framework for ulcerative colitis research, while the supplied record leaves important questions about model scope, quantitative evidence, and relevance to human disease.

• What the CYR61–Migrasome Study Shows—and Misses

  2026-10-12

  The supplied 2025 study supports a model in which CYR61-associated migrasomes may help restore migration and osteogenic behavior in irradiated BMSCs, but its findings do not establish clinical efficacy or compare protein-preservation reagents. Product claims for an MS-compatible Protease Inhibitor Cocktail should therefore remain separate from the study’s biological conclusions.

• PRINT: RNA-Mediated Safe-Harbor Insertion

  2026-10-10

  A Nature Biotechnology study introduces PRINT, an RNA-only strategy that uses avian R2 retroelement proteins to direct transgene synthesis into a multicopy human safe-harbor locus. The reported results show substantial insertion of kilobase-scale transgenes in cultured human primary cells, while also defining important limitations around template recognition, junction verification, and transferability beyond the tested model.

• Entecavir and HBV Resistance: Meta-Analysis Findings

  2026-10-09

  Lumley and colleagues provide the first systematic review and meta-analysis to pool sequence-defined hepatitis B virus resistance estimates for entecavir and tenofovir over time. The analysis found low cumulative resistance to entecavir in treatment-naive populations, substantially higher resistance among nucleos(t)ide-experienced participants, and no pooled tenofovir resistance signal—although important evidence gaps limit interpretation.

• Sodium Chloride B7288: Product Overview

  2026-10-09

  Sodium chloride B7288 is a supplier-listed inorganic salt with the identity NaCl, molecular weight 58.44, CAS 7647-14-5, and stated purity of 98%. No matched paper evidence is available for this specific product.

• Uridine, Trisodium Salt: Evidence and Scope

  2026-10-08

  Explore Uridine, Trisodium Salt as a biochemical reagent for RNA metabolism and vascular research, while separating its established biochemical relevance from the RNA-only PRINT genome-engineering findings reported in Nature Biotechnology.

• Carbenoxolone Disodium: Product Overview

  2026-10-08

  Carbenoxolone disodium (SKU A8389) is listed by APExBIO as a research compound associated with 11β-hydroxysteroid dehydrogenase, gap junction communication, and related glucocorticoid signaling. No matched paper evidence was provided, so performance, selectivity, and disease-model relevance cannot be independently assessed.

• High-Yield Rabbit Pharming: What the Study Shows

  2026-10-07

  Song et al. developed a targeted rabbit knock-in line that uses the CSN2 regulatory region to drive milk-associated expression of the tdTomato reporter. Homozygous animals reportedly reached 15–20 g/L in milk, supporting targeted promoter selection as a promising strategy, although the study remains an early platform demonstration rather than proof of therapeutic-product performance.

• Toremifene Citrate: Evidence from the Reference Paper

  2026-10-07

  The reference paper presents Toremifene Citrate as a nonsteroidal antiestrogen and oral selective estrogen receptor modulator for hormone receptor-positive or unknown-status advanced breast cancer in postmenopausal women. Its principal contribution is a clinically oriented synthesis connecting estrogen receptor pharmacology with comparative efficacy, safety monitoring, drug interactions, and oncology nursing considerations.

• D-Mannitol B2090: Product Overview

  2026-10-06

  D-Mannitol B2090 is a supplier-described biochemical reagent for conceptual osmotic regulation research, renal function studies, and diuretic mechanism investigation. No matched paper evidence was provided for this specific product.

• Leucovorin Calcium in Gastric Cancer Models

  2026-10-06

  Leucovorin Calcium, or calcium folinate, is relevant to research on reduced folate biology and methotrexate response. A 2025 gastric cancer assembloid study shows why stromal context can change drug sensitivity, but it does not directly establish leucovorin-specific effects or clinical utility.

• Uridine, Trisodium Salt: What the Evidence Shows

  2026-10-05

  Uridine, Trisodium Salt is examined here as a nucleoside analog within RNA metabolism, vascular biology, and RNA-mediated genome engineering. Rather than treating a commercial reagent as proof of platform performance, this evidence-led analysis separates supplier specifications from what PRINT research actually demonstrated.

7950 records 1/530 page Next 12345 下5页 Last page